What this means
To investigate the protective effects of dihydroquercetin (DHQ) on mitochondrial function in primary hepatocytes from patients with chronic liver failure (CLF) and discuss the underlying molecular mechanism. Blood samples from 15 CLF patients and 15 healthy subjects were retrospectively analyzed.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- Not stated
- Kind of research
- A study
The science
- Original title
- Dihydroquercetin alleviates mitochondrial dysfunction and inhibits NLRP3-mediated pyroptosis in primary hepatocytes from chronic liver failure patients.
- Authors
- Shen A, Wang P, Wu B et al.
- Journal
- American journal of translational research
- Published
- Aug 22, 2026
- Study type
- Study
- PMID
- 42630864 ↗
Abstract
Background
To investigate the protective effects of dihydroquercetin (DHQ) on mitochondrial function in primary hepatocytes from patients with chronic liver failure (CLF) and discuss the underlying molecular mechanism.
What they did
Blood samples from 15 CLF patients and 15 healthy subjects were retrospectively analyzed. Primary hepatocytes were isolated using a modified two-step collagenase perfusion method. The optimal concentration of DHQ (20 μmol/L) was determined using the Cell Counting Kit-8 (CCK-8) assay. Cells were divided into a control group, a plasma group, and a DHQ intervention group. The assessed indicators included cell viability (CCK-8), apoptosis rate (flow cytometry), inflammatory factors (IL-1β, IL-6, TNF-α; ELISA), oxidative stress markers (MDA, SOD, GSH-Px), mitochondrial function (JC-1 staining, mtDNA/nDNA ratio) and related protein expression (Western blot).
What they found
DHQ adjunctive therapy reduced serum circulating mitochondrial DNA levels in patients with CLF, increased serum SOD2 and Humanin expression, inhibited activation of the NLRP3-mediated pyroptotic pathway, improved remission rates of decompensated complications, and showed favorable safety and tolerability in patients with end-stage liver diseases. In vitro, hepatocyte viability was markedly decreased in the CLF group, with increased apoptosis, elevated IL-1β, IL-6, TNF-α, and MDA levels, as well as declined SOD and GSH-Px activities. DHQ reduced apoptosis, up-regulated mitochondrial functional markers (SOD2, Humanin), restored JC-1 red/green fluorescence ratios, inhibited NLR family pyrin domain-containing 3 (NLRP3) inflammasome activation, and suppressed the caspase-1/IL-1β axis. DHQ exerts multidimensional protective effects on hepatocytes, providing a novel strategy and clinical evidence for mitochondria-targeted CLF therapy.
The authors' abstract, grouped under plain headings from its own section labels.
Shen A, Wang P, Wu B et al. Dihydroquercetin alleviates mitochondrial dysfunction and inhibits NLRP3-mediated pyroptosis in primary hepatocytes from chronic liver failure patients. American journal of translational research. 2026. doi:10.62347/IFRP1860. PMID: 42630864. https://pubmed.ncbi.nlm.nih.gov/42630864/
Related research
Home exercise may change muscle in people with kidney disease
A small trial found changes in muscle blood vessels and fewer fibrosis-linked cells after 12 weeks of home exercise. Only 25 people took part, so this does not prove the exercise caused lasting muscle benefits.
Protein NEDD4 may protect disc cells from aging and cell death in a lab test
Researchers grew disc cells in a dish with an inflammation signal. Boosting NEDD4 eased aging and cell death, and it broke down another protein called PTEN. More tests in living animals and more checks are still needed.
Effects of Supplementation in Masters Athletes and Older Adults: A Narrative Review.
Supplementation use in athletes is common and increasing in popularity, especially for adults seeking improvements in athletic performance.
Review of copper peptide GHK-Cu studies finds many lab results but few human trials
Researchers read 64 studies on GHK-Cu, a copper-linked peptide, and found much lab and animal work. They say well-designed human trials using microneedles are still needed.
Humanin treatment eased heart damage in diabetic mice
Mice with diabetes that got daily humanin for 15 days had less stress, inflammation, and cell death in the heart. This was tested in mice only, so it does not show the same would happen in people.
Humanin protein family may help steer cell stress responses
Researchers mapped how Humanin-related proteins connect to other proteins in a computer network. They suggest these proteins may guide stress responses, not just act alone. This is a model, so it does not show these proteins work this way in people.
See all research on Collagen peptides →